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Background: Infantile neuroaxonal dystrophy (INAD) is a rare autosomal-recessive neurodegenerative disorder.
Patients with INAD usually show neurological symptoms with infant onset and die in childhood. Recently, it was
reported that mutations in the PLA2G6 gene cause INAD, but neuropathological analysis of genetically confirmed
individuals with neuroaxonal dystrophy has been limited.
Results: Here, we report a Japanese individual with neuroaxonal dystrophy associated with compound
heterozygous mutations in the PLA2G6 gene. A novel splice-site mutation resulting in skipping and missense
mutations (p.R538C) in exon 9 was identified in the patient. This patient initially presented with cerebellar ataxia at
the age of 3 years, which was followed by symptoms of mental retardation, extrapyramidal signs, and epileptic
seizure. The patient survived until 20 years of age. Neuropathological findings were characterized by numerous
axonal spheroids, brain iron deposition, cerebellar neuronal loss, phosphorylated alpha-synuclein-positive Lewy
bodies (LBs), and phosphorylated-tau-positive neurofibrillary tangles. In particular, LB pathology exhibited a unique
distribution with extremely severe cortical involvement.
Conclusions: Our results support a genetic clinical view that compound heterozygous mutations with potential
residual protein function are associated with a relatively mild phenotype. Moreover, the severe LB pathology
suggests that dysfunction of the PLA2G6 gene primarily contributes to LB formation.
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Neurodegeneration with brain iron accumulation (NBIA)
describes a group of progressive neurodegenerative disor-
ders that are pathologically characterized by the presence
of axonal spheroids and iron deposition in the brain [1-3].
These neurodegenerative diseases consist of a clinically
and genetically heterogeneous group of disorders, includ-
ing pantothenate kinase-associated neurodegeneration
(PKAN, formerly known as Hallervorden-Spatz disease),
infantile neuroaxonal dystrophy (INAD), and an unknown
gene mutation-linked idiopathic neuroaxonal dystrophy* Correspondence: myoshida@aichi-med-u.ac.jp
5Institute for Medical Science of Aging, Aichi Medical University, Aichi, Japan
Full list of author information is available at the end of the article
© 2013 Riku et al.; licensee BioMed Central Ltd
Commons Attribution License (http://creativec
reproduction in any medium, provided the or[1,2,4]. PKAN is caused by mutations in the pantothenate
kinase 2 (PANK2) gene, which accounts for the majority
of NBIA patients [2]. Recently, it was reported that muta-
tions in the phospholipase A2 group VI (PLA2G6) gene
cause INAD [5], which is a rare autosomal-recessive neu-
rodegenerative disorder. Patients with INAD usually
present with psychomotor regression, truncal hypotonia,
progressive ataxia, extrapyramidal symptoms, fast waves
on an electroencephalogram, and neuro-ophthalmological
abnormalities (e.g., optic atrophy, nystagmus, and strabis-
mus) with infant onset and die in childhood [1,4,6]. How-
ever, in rare cases, patients with NAD caused by PLA2G6
mutations present with heterogeneous neurological mani-
festations with onset past infanthood and survive until. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Riku et al. Acta Neuropathologica Communications 2013, 1:12 Page 2 of 11
http://www.actaneurocomms.org/content/1/1/12adulthood with a slower disease progression [1,7,8]. In
addition, mutations of the PLA2G6 gene cause early onset
dystonia-parkinsonism (PARK-14), which is clinically dis-
tinguished from NAD by good L-dopa responsiveness,
L-dopa–induced dyskinesia, and dementia. These charac-
teristics have been typically observed in patients with an
older age of onset and with a longer disease duration com-
pared to NAD, with no evidence of cerebellar symptoms
[9]. Thus, these clinical phenotypes are collectively termed
as PLA2G6-associated neurodegeneration [9].
We report a Japanese individual with neuroaxonal dys-
trophy that was associated with a novel compound het-
erozygous mutation in a splicing site of the PLA2G6
gene. The clinical phenotype of this patient was atypical
for INAD, occurred during late disease onset, and
prolonged the disease course. Histopathological data re-
vealed the presence of neuroaxonal spheroids, brain iron
depositions, and cerebellar degeneration. Moreover, nu-
merous Lewy bodies (LBs) and neurofibrillary tangles
(NFTs), which are pathological hallmarks of Parkinson’s
disease (PD) and Alzheimer’s disease (AD), respectively,
were observed. Until recently, neuropathological analysis
of genetically confirmed neuroaxonal dystrophy has been
strongly limited due to a small number of patients [1,8].
In this study, we describe the clinicopathological charac-
teristics of the patient and discuss the neuropathological




The patient was a Japanese man who died at 20 years of
age. He exhibited normal development until the age of
3 years, at which time his parents noted his slurred
speech and unstable gait. There was no evidence of a
consanguineous marriage in any of his relatives. His
grand-aunt had been diagnosed with “parkinsonism”,
and she died at the age of 60; however, her clinical diag-
nosis was uncertain. At the age of six, the patient was re-
ferred to our hospital due to a progressive gait
disturbance and dysarthria. A neurological examination
revealed cerebellar ataxia, bradykinesia, mental retard-
ation, and hyperreflexia in the lower limbs without
pathological reflexes. Truncal hypotonia and abnormal-
ities in eye movement were not observed. Cerebral com-
puted tomography (CT) showed severe cerebellar
atrophy. The patient was clinically diagnosed with juven-
ile spinocerebellar degeneration, and taltirelin was ad-
ministered for his ataxia; however, it did not have an
effect. At the age of 12, cerebral magnetic resonance im-
aging (MRI) revealed severe atrophy of the cerebellum
and mild atrophy of the frontal lobes (Figure 1a-c). The
patient gradually became bedridden until the age of 15
and started experiencing repetitive generalized seizures.He was mainly treated with sodium valproate and
phenobarbital. At the age of 18, he was re-admitted to
our hospital, although he was nearly bedridden and
could barely sit in a wheelchair at that time. Neuro-
logical examination revealed severe dystonia and rigidity
in his limbs and neck, a masked face, and severe cerebel-
lar ataxia. His tendon reflexes showed hyperreflexia in
the upper limbs and were abolished in his lower limbs.
Moreover, his plantar responses were flexor. CT and
MRI (Figure 1d-f ) revealed severe cerebellar and fronto-
temporal lobe atrophy. The cerebral atrophy was more
progressive compared to the atrophy observed when he
was 12 years old. By T2-weighted imaging (T2WI), the
bilateral globus pallidus (GP) and putamen exhibited
low signal intensity. Tc99m-ECD-single-photon emission
computed tomography revealed hypoperfusion in the
fronto-temporal lobes and cerebellum (Figure 1g). An
electroencephalogram showed multifocal spikes and
theta waves in the right hemisphere in the absence of
fast waves. The results of the nerve conduction study on
the four limbs were normal. After discharge, a higher
dose of valproate reduced the frequency of the patient’s
seizures; however, his rigidity and dystonia showed no




The postmortem interval was 5 hours. The brain and
spinal cord were fixed in 20% neutral formalin. Samples
obtained from the main representative regions of the
brain and spinal cord were embedded in paraffin, sec-
tioned into 4.5-μm-thick slides, and stained with
hematoxylin and eosin (H&E), Klüver-Barrera staining,
Prussian blue methods, and Gallyas-Braak (GB) staining.
Immunohistochemical studies were performed on 4.5-
μm-thick sections using an ENVISION kit (Dako) with
diaminobenzidine (DAB; Wako, Osaka, Japan) as a
chromogen. The primary antibodies used were anti-
phosphorylated alpha-synuclein (p-α-synuclein) (pSyn#64,
monoclonal mouse, 1:1000; Wako Pure Chemical Indus-
tries, Osaka, Japan), anti-ubiquitin (polyclonal rabbit,
1:2000; Dako), anti-amyloid-beta peptide (6F/3D,
monoclonal mouse, 1:200; Dako), phosphorylated tau
(p-tau) (AT8, monoclonal mouse, 1:2000; Innogenetics,
Zwijndrecht, Belgium), anti- TDP-43 (TARDBP, polyclonal
rabbit, 1:2500; ProteinTech, IL, USA), and anti-
phosphorylated neurofilament (p-NF) (2F11, monoclonal
mouse, 1:600; Dako). For double-immunofluorescence la-
beling, brain tissues obtained from the amygdala, oculo-
motor nucleus, and substantia nigra were sectioned into
4.5-μm-thick slides. The primary antibodies were anti-
p-α-synuclein antibody and AT8 antibody. The secondary
antibodies were goat anti-mouse IgG coupled with either
Figure 1 Magnetic resonance imaging (MRI) and Tc99m-ECD-single-photon emission computed tomography (SPECT) of the patient.
a-c MRI at age 12. There was mild atrophy of the frontal cortex and slightly low intensity in the globus pallidus on T2-weighted images (T2WI)
(a, b). The saggital section of the T1WI exhibited cerebellar atrophy (arrow) (c). d-f MRI at age 18. Low signal intensity in the globus pallidus
(arrowhead) and atrophy of the temporal lobes was clear on the T2WI (d). The frontal lobes showed severe atrophy (e). The saggital section of
the T1WI exhibited severe cerebellar atrophy (arrow) and thinness of the corpus callosum (f). An ECD-SPECT, at age 18, revealed hypoperfusion of
the frontotemporal lobes and cerebellum (g).
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Probes, OR, USA) or Alexa Fluor 488 (1:300, emission
peak 517 nm, Molecular Probes). The slides were exam-
ined via confocal microscopy at × 200 and × 400 magnifi-
cation using a Zeiss LSM 710 laser scanning confocal
microscope.
For electron microscopy, sections from the cingulate
gyrus were fixed in 4% glutaraldehyde. The sections were
washed in phosphate buffer, postfixed with osmium tet-
roxide, dehydrated in a graded series of ethanol, and em-
bedded in Epon. Ultrathin sections were stained with
uranyl acetate and lead citrate.
Western blotting analysis of α-synuclein
Proteins expressed in the amygdala and parahippocampal
gyrus of the autopsied patient and three control subjects
were extracted as previously described [10,11]. Briefly, we
fractionated the samples by resolubilization in increasingly
stringent buffers (Tris-buffered saline, 1% Triton X-100,
1% sarcosyl, 8 M urea) as previously described. Equalamounts of supernatant protein were subjected to sodium
dodecyl sulfate-polyacrylamide gel electrophoresis and im-
munoblotting. The mouse monoclonal antibody LB509
(Zymed Laboratories, South San Francisco, California)
was used to detect α-synuclein. The monoclonal antibody
pSyn#64 (Wako, Japan) specifically recognizes phosphory-
lated α-synuclein at serine 129 [12].
Genetic analysis
Genomic DNA was extracted from the frozen liver tissue
of the patient using a standard procedure. Mutational
analysis was performed using sequences of both strands
of all of the PCR-amplified coding exons and the
flanking intronic sequences of PLA2G6, PANK-2, SNCA,
parkin, PINK-1, and DJ-1. Expansion of the CAG repeats
of the SCA1, SCA3, DRPLA, and Huntington’s disease
genes was also examined. Genetic analysis of PLA2G6
was also performed in the patient’s parents. Total RNA
was isolated from frozen brain tissue of the patient, and
cDNA was synthesized using a High-Capacity cDNA
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was performed using primer pairs to amplify the coding
regions of the PLA2G6 gene spanning exons 8–13 (5′-
caacgtggagatgatcaagg-3′ and 5-gtcagcatcaccttgggttt-3′)
and exons 9–13 (5′-ggaaggcgatcttgactctg-3′ and 5′-




The patient’s height was 150 cm, and his body weight
was 39 kg. The brain weighed 890 g before fixation.
Grossly, the cerebral hemispheres showed severe atro-
phy, particularly in the fronto-temporal cortex. In the
brain sections, the most striking pathological finding
was a light yellow-brown discoloration of the substantiaFigure 2 The macroscopic and microscopic findings in the patient. a,
periaqueductal gray matter demonstrated yellow-brown discoloration (arro
the granule cell layer was not visible. d The cerebellar granule cells were m
e The cingulate gyrus showed gliosis and numerous axonal spheroids (arro
were labeled by anti-phosphorylated neurofilament antibody. h In the cere
dystrophic axons of the Pcs and highly reduced parallel fibers. i Many iron-
granules were evident after Prussian blue staining. Bar = 50 μm. Hematoxyl
immunohistochemistry (g, h), and Prussian-blue staining (j).nigra (SN), periaqueductal gray matter, putamen, caud-
ate head, and GP (Figure 2a,b). The cerebellum was
greatly reduced in size; its overall convolution pattern
was retained, but the individual folia were shrunken.
Histopathologically, severe neuronal loss and gliosis
were observed in the cerebral cortex, brainstem gray
matter, and cerebellar cortex. In the cerebrum, neuronal
loss was marked in the cingulate gyrus, fronto-temporal
cortex, insular cortex, amygdala, and hippocampus. In
the brain stem, neurons in the SN were markedly de-
pleted, and the remaining neurons had low melanin con-
tent. The locus ceruleus (LC) showed moderate
neuronal loss, but the neurons in the dorsal motor nu-
cleus of the vagus were relatively spared. The cerebellar
cortex showed severe neuronal loss (Figure 2c,d), par-
ticularly in the granule cell (gc) layer, and the parallelb The globus pallidus, putamen, caudate, substantia nigra, and
wheads). c Grossly, the cerebellar cortex showed severe atrophy, and
arkedly depleted, and ectopic Purkinje cells (Pcs) were found (arrows).
ws). f, g The putamen also contained numerous axonal spheroids that
bellum, anti-phosphorylated neurofilament immunostaining revealed
positive granules were observed in the putaminal neuropil. j These
in and eosin staining (c-f, i), phosphorylated neurofilament
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(Figure 2c,d,h). Purkinje cells (Pcs) were severely de-
pleted and often ectopically scattered at random in the
molecular layer (Figure 2d). The spinal cord exhibited
myelin pallor of the gracile fasciculus with gliosis.
In addition, we observed axonal spheroids throughout
the central nervous system (CNS), particularly in the
cerebral cortex, putamen (Figure 2e-g), caudate nucleus,
nucleus accumbens, hypothalamus, SN, gracile nucleus,
and spinal cord. The cerebellum contained numerous
dystrophic axons called ‘torpedoes’ in the Pc and gc
layers (Figure 2h). The diameters of the spheroids
ranged from 10 to 20 μm, but the spinal cord contained
larger-sized spheroids of 40–70 μm in diameter. Various
spheroids were immunoreactive against anti-p-NF
(Figure 2g,h) and anti-ubiquitin antibodies. We foundFigure 3 Lewy body (LB) and neurofibrillary tangle (NFT) pathology o
type” LBs with core and halo (arrows) structures. b and inset In the cingul
there were “cortical-type” LBs without core and halo structures (arrows). c a
immunohistochemistry showed abundant LBs in the substantia nigra (c) an
horn (f), p-α-synuclein-positive LBs and LNs were strikingly abundant. g an
cortical LBs in a cortical neuron (asterisk), which consisted of granular and
a clear central zone density. i - l The pyramidal neuron in the hippocampa
AT-8 antibody using the Gallyas-Braak method. m-o Confocal microscopy o
red), which often co-labeled with AT8 (n, green) in the same neurons (o, m
50 μm; (f) = 250 μm; (g) = 2 μm; (h) = 0.2 μm; (a-inset), (b-inset), (j), (k), and
immunohistochemistry (c-f), AT8 immunohistochemistry (i, k), and Gallyas-no spheroids in the sympathetic ganglia, dorsal root gan-
glia, spinal roots, peripheral nerve fibers in the skin, or
the enteric plexus. Brown-pigmented, Prussian blue-
positive iron granules were scattered around the vessels
and throughout the neuropil in the putamen, internal
segment of the GP, caudate nucleus, thalamus, pars
compacta of the SN, and periaqueductal gray matter
(Figures 2i,j, 4c).
Furthermore, severe LB pathology was observed
throughout the brain (Figures 3a-f, 4a). In immunohisto-
chemistry, anti-p-α-synuclein (Figure 3c-f), anti-p-NF,
and anti-ubiquitin antibodies strongly labeled LBs. Im-
munohistochemistry using anti-p-α-synuclein antibody
also revealed numerous dilated and sausage-like dys-
trophic neurites in the neuropil, which have been re-
ferred to as Lewy neurites (LNs) (Figure 3d,e). In thef the patient. a and inset The substantia nigra contained “brainstem-
ate gyrus, the neuropil showed spongy changes in the deep layer, and
nd d Anti-phosphorylated alpha-synuclein (p-α-synuclein)
d cingulate gyrus (d). e and f In the hypothalamus (e) and Ammon’ s
d h Electron microscopy of a neuron in the cingulate gyrus showed
filamentous structures. The filaments were arranged at random without
l cortex contained abundant NFTs and threads that were positive for
f the amygdala revealed immunoreactivity against p-α-synuclein (m,
erged). Bar (a), (b), (c), and (i) = 100 μm; (d), (e), (m), (n), and (o) =
(l) = 20 μm. Hematoxylin and eosin staining (a, b, j), p-α-synuclein
Braak staining (l).
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lacked core and halo structures, and LNs were diffusely
found (Figure 3b,e) with striking spongiform alterations
(Figure 3b). The distribution and density of LBs and LNs
exceeded what has been observed in advanced PD or
DLB in the neocortical stage [13,14]. They were most
abundant in the cingulate gyrus, amygdala, anterior
hippocampus, CA2 region of the posterior hippocampus,
and hypothalamus. LBs with a core and halo (brainstem-
type LBs) were observed predominantly in the nucleus
basalis of Meynert, SN, oculomotor nucleus, and LC
(Figure 3a,c). In the cerebellum, neuronal cytoplasm and
neurites of the dentate nucleus rarely contained p-α
-synuclein-positive structures. In contrast, the olfactory
bulbs and dorsal motor nucleus of the vagus contained
only mild LB pathology. There were no p-α-synuclein-
positive structures in the peripheral sympathetic ganglia,
dorsal root ganglia, cardiac sympathetic nerve fibers, or
nerve plexuses in the gastroenteric organs. Numerous p-
tau-positive NFTs were also found predominantly in the
limbic system (Figures 3i-l, 4b). The abundance of NFTs
corresponded to AD in Braak stage IV [15], however,
Aβ-positive neuritic plaques and amyloid deposits were
absent. Additionally, TDP-43-positive inclusions were
absent in this patient.
Using double-immunofluorescence labeling in the
amygdala, p-tau-positive NFTs and p-α-synuclein-posi-
tive cortical LBs often co-labeled in the same neuronFigure 4 Schema of the distribution of Lewy bodies (LBs), neurofibrill
diffusely spread in the cerebral cortices and were most abundant in the lim
(SN), and locus ceruleus. The olfactory bulbs and dorsal motor nucleus of t
-synuclein-positive structures in the peripheral sympathetic ganglia and do
system, which corresponded to Alzheimer’s disease in Braak stage IV. c Iron
the globus pallidus, caudate nucleus, SN, and periaqueductal gray matter. D
Semi-quantitative scale for LBs and NFTs: dot-pattern = 1–10, gray = 10–20,
Iron-positive granules: dot-pattern =mild, gray =moderate, black = severe.(Figure 3m-o). In contrast, neurons in the midbrain did
not show co-labeling of LBs and NFTs (data not shown).
On electron microscopy, LBs from the cingulate gyrus
consisted of closely packed 6- to 10-nm-thick granular
and filamentous structures. The filaments were arranged
at random without a clear central zone density. These
findings were similar those observed in cortical-type LBs
in the DLB [16] (Figure 3g,h).
Western blotting analysis of α-synuclein
To biochemically characterize the accumulation of α-
synuclein, we sequentially extracted proteins from the
amygdala and parahippocampal gyrus of the autopsied
male subject using buffers with increasing capacities to
solubilize proteins. In the control sample, immunoblot-
ting analysis using anti-α-synuclein LB509 sho-
wed an approximately 15-kDa band corresponding to
monomeric α-synuclein in Tris–HCl- and Triton
X-100-soluble fractions (Figure 5a). In contrast, an ~15-
kDa α-synuclein band was predominantly visualized in
sarkosyl-insoluble urea-soluble fractions in the brain
(Figure 5a). In addition to the ~15-kDa band, an ~30-
kDa band corresponding to α-synuclein dimers was
observed in the insoluble fractions extracted from the
patient’s brain samples. Importantly, the ~15- and ~30-
kDa bands found in the urea-extracted fractions were re-
active to anti-pSyn#64 antibody (Figure 5b), indicating
that the accumulated α-synuclein in the patient brainary tangles (NFTs), and iron deposition in the patient. a LBs were
bic system, hypothalamus, nucleus basalis of Meynert, substantia nigra
he vagus contained only mild LB pathology. There were no p-α
rsal root ganglia. b NFTs were predominantly observed in the limbic
-positive granules were found in the putamen, internal segment of
RG: dorsal root ganglia, Olf: olfactory bulb, SG: sympathetic ganglia.
black > 20. Number of lesions in a field observed using a 10× objective.
Figure 5 Biochemical analysis of α-synuclein in brain tissues. a The samples were sequentially fractionated by resolubilization with
increasingly stringent buffers containing Tris-buffered saline, Triton X-100, sarkosyl, and urea. The samples were analyzed using the α-synuclein
antibodies LB509 and pSyn#64. In the urea-extracted fraction, a phosphorylated α-synuclein band at approximately at ~15 kDa (arrow) was
substantially accumulated in the brain (amygdala and parahippocampus) of the autopsied patient. Conversely, the level of α-synuclein in the Tris-
and Triton X-100-soluble fractions was decreased. Anti-β-actin immunoblotting served as a loading control (bottom panel). b α-Synuclein-reactive
fragments of dimers migrating at approximately ~30 kDa (arrowhead) and a smear at higher molecular weights were abundant in the urea-
extracted fraction of the patient’s brain.
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showed large amounts of α-synuclein-reactive high-
molecular-weight smears, which might have represented
α-synuclein oligomers (Figure 5b).
Genetic analysis
Sequence analysis revealed that the patient carried com-
pound heterozygous mutations in the PLA2G6 gene. A
novel splice-site mutation in exon 9 (c.1187-2A > G) and
a missense mutation (c.1612C > T, p.R538C) in exon 12
(Figure 6a) were identified in the patient. These muta-
tions were absent in 120 normal control subjects. The p.
R538C missense mutation was previously reported in pa-
tients with classical INAD [5]. Genetic analysis of the
unaffected parents of the patient revealed that the father
and mother were heterozygous carriers of the p.R538C
missense and splice-site mutations, respectively
(Figure 6b). No mutations were identified in PANK2,
SNCA, parkin, DJ-1, or PINK-1. There was no patho-
logical expansion of CAG repeats in the genes associated
with SCA1, SCA2, DRPLA, or Huntington’s disease.
We next investigated whether the splice-site mutation
caused an alteration in the splicing of PLA2G6 using
RT-PCR analysis of total RNA extracted from the pa-
tient’s frozen tissue. To examine the mRNA expression
of PLA2G6 in the patient’s brain, two primer pairs were
designed to amplify cDNA fragments encompassing
exons 8 to 13 (primers A-C) and 9 to 13 (primers B-C),
respectively (Figure 6c). In the control samples, twoalternative splicing variants were amplified using the pri-
mer pairs A-C. Sequence analysis of the fragments in
the control samples revealed that these variants
corresponded to two previously reported isoforms of
PLA2G6 mRNA, with and without the 162-bp exon 9,
respectively [17]. In the patient, the 700-bp fragment
containing exon 9 was nearly undetectable by RT-PCR
using the primer pair A-C. RT-PCR amplification using
the primer pair B-C revealed that the 600-bp cDNA
fragment containing exon 9 found in the control sam-
ples was less expressed in the patient (Figure 6d).
Discussion
INAD is a rare, autosomal-recessive neurodegenerative
disorder with infant onset, and patients usually die in
childhood [1,4,6]. In an INAD cohort with PLA2G6 mu-
tations previously described by Gregory et al., symptoms
began between 5 months and 2.5 years of age [1]. Wu
et al. reported that half of INAD patients with a disease
course of 2–5 years became vegetative [6]. In this study,
the patient’s initial neurological manifestation was cere-
bellar ataxia at the age of 3 years, which was later ac-
companied by mental retardation, dystonia, and seizures.
The patient survived until the age of 20 years. His
clinical phenotype was atypical for INAD; the disease
onset and progression were delayed and slower, and
there was no indication of truncal hypotonia, neuro-
ophthalmologic abnormalities, or fast rhythms on an
electroencephalogram throughout the clinical course.
Figure 6 Identification of compound heterozygous mutations in PLA2G6 in the patient. a Mutation analysis of PLA2G6 in the patient.
Sequence analysis of the patient’s genomic DNA revealed two mutations: a 5′ splice-site mutation in exon 9 (c.1187-2A > G) and a missense
mutation (c.1612C > T, p.R538C) in exon 12. The capital and small letters represent nucleotides in exons and introns, respectively. b Pedigree of
the patient with PLA2G6 mutations. Circle, female; square, male; slash through symbol, deceased individual; closed symbol, affected individual. An
arrow denotes the proband. The father and mother each carried one of the compound heterozygous mutations found in the patient. c
Schematic illustration of exon-intron structure of PLA2G6. Boxes represent exons. The positions of the mutations in the patient are shown. Two
primer pairs were designed to amplify cDNA fragments encompassing exons 8 to 13 (primers A-C) and 9 to 13 (primers B-C). d Reverse
transcription (RT)-PCR analysis of the patient’s brain. In the patient, a 700-bp fragment containing exon 9 was nearly undetectable by RT-PCR
using the primer pair A-C. RT-PCR amplification using the primer pair B-C revealed a 600-bp cDNA fragment containing exon 9, which was
recognized in control samples but was less noticeable in the autopsied patient. Amplification of β-actin mRNA was used as an internal control.
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patient registry with PLA2G6 mutation who exhibited
variable clinical phenotypes with late onset (average
4.4 years, range 1.5-6.5 years) [1,2]. This phenotype was
referred to as atypical neuroaxonal dystrophy (ANAD).
The clinical phenotype of our patient might be classified
as ANAD. Moreover, patients with a slower disease pro-
gression and heterogeneous clinical pictures have been
occasionally described in other series of INAD patients
[7,8]. Currently, it is speculated that patients with mu-
tant forms of the PLA2G6 gene display a complete ab-
sence of protein, which is associated with a severe INAD
profile, whereas patients with compound heterozygous
mutations potentially exhibit residual protein function
and have a less severe phenotype [18]. Our geneticfindings further support this genotype-phenotype
correlation.
To the best of our knowledge, there have only been
two reports that describe the CNS neuropathology of
genetically confirmed patients with a PLA2G6 gene mu-
tation, as summarized in Table 1 [1,8]. The neuropatho-
logical features, including neuroaxonal spheroids,
cerebellar degeneration, and brain iron accumulation,
were described in INAD before the discovery of its
causal gene [3]. Moreover, the presence of LB and NFT
pathology has been described in neuroaxonal dystrophy
with PLA2G6 gene mutation [1,8]. On the basis of dis-
ease onset, patients 1–4 in Table 1 might be classified as
ANAD or early onset dystonia-parkinsonism; however,
no components of the pathological findings differed


















1[8] 18 y 36 y + NA gc and Pc + + +
2[1] 3 y 23 y + - gc and Pc + + +
3[8] childhood 18 y + NA gc and Pc + + +
4[8] 14 m 8 y + NA gc and Pc + + +
5[8] infant 8 y + NA NA + - NA
Our
patient
3 y 20 y + - gc and Pc + + +
Abbreviation: CNS = central nervous system; gc = granule cell; NA = not assessed; Pc = Purkinje cell; PNS = peripheral nervous system.
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tient, neuronal loss, LB pathology, NFT pathology, and
the presence of axonal spheroids were marked in the
limbic system, fronto-temporal lobes, and SN. These
pathological findings might be responsible for progres-
sive cortical atrophy, psychomotor regression, and par-
kinsonism. Iron deposition broadly extended throughout
the basal ganglia and midbrain compared to what was
predicted from the T2 low-intensity area on MRI. Fur-
thermore, loss of cerebellar neurons, particularly granule
cells, was both striking and consistent with the cerebel-
lar ataxia that was diagnosed in the early phase of the
disease.
LB pathology has been identified in all six patients
reviewed [1,8]. A recent study reported that LB path-
ology was not observed in patients with the PANK2 gene
mutation [19]. Moreover, earlier case reports describing
neuroaxonal dystrophy or brain iron accumulation with
abundant LBs may have been describing patients with
PLA2G6 gene mutations [20-22]. We demonstrated that
the morphological, ultrastructural, and biochemical
properties of LBs in this patient were identical to those
in PD and diffuse Lewy body disease (DLB) patients
[12,16,23]. Furthermore, the spatial distribution of LB
pathology showed cortical involvement that exceeded
that of the end stage of sporadic PD or the diffuse neo-
cortical type of DLB [13,14]. Previous autopsy reports of
INAD and ANAD have also described marked cortical
involvement of LBs [1,8]. In contrast, the dorsal nucleus
of the vagus nerve and olfactory bulbs were mildly af-
fected in our patient, and the cardiac nerve fibers and
enteral nerve plexus contained no p-α-synuclein aggre-
gation, although these regions have been described as
constant and early affected regions in sporadic PD and
DLB [24,25]. The distribution of LB pathology in INAD
and ANAD may tend to be more severe in the cerebral
cortices compared to the medulla oblongata or periph-
eral autonomic neurons, which differs from the typical
topography observed in sporadic PD and DLB. NFT
pathology was another neuropathologial characteristic ofinterest in patients with INAD and ANAD. In our pa-
tient, NFTs and p-tau-positive threads predominantly
appeared in the limbic system, which was similar to AD
in Braak’s stage IV [15]. However, neither this nor
previously reported patients with PLA2G6 gene muta-
tions exhibited senile plaques, which contrasts with the
typical neuropathology observed in AD [15]. Import-
antly, NFT pathology has been frequently observed in
patients with sporadic PD or DLB [26,27], and LBs and
NFTs often coexist in the same neurons, particularly
those located in the limbic areas [26]. Our double-
immunofluorescence results are consistent with findings
in sporadic PD and DLB. Thus, further investigation in
multiple patients on the association between NFTs and
LB pathology and the implications of NFT pathology in
INAD and ANAD are required.
The PLA2G6 gene encodes iPLA2-Via, which is a crit-
ical protein in lipid membrane homeostasis [28]. Recent
reports using Pla2g6-knockout mice demonstrated the
presence of axonal spheroids in which tubulovesicular
membranes accumulated [29-32]. In contrast, the patho-
logical mechanism that contributes to LB formation in
INAD and ANAD remains to be elucidated. LBs are sec-
ondarily present in several situations other than sporadic
PD/DLB (e.g., sporadic or familial AD or Niemann-Pick
disease type C) or may be incidentally found in healthy
elderly individuals [33-36]. However, our neuropatho-
logical results and previous studies have demonstrated
that LB pathology in patients with PLA2G6 gene muta-
tions shows a high prevalence and displays an extremely
severe phenotype, particularly in the cerebral cortices.
These findings suggest that defects in PLA2G6 primarily
contribute to the formation of LBs.
Conclusions
Our results demonstrate the clinical heterogeneity of
neuroaxonal dystrophy with PLA2G6 gene mutations
and support a genetic clinical view that compound het-
erozygous mutations that potentially result in residual
protein function are associated with a less severe
Riku et al. Acta Neuropathologica Communications 2013, 1:12 Page 10 of 11
http://www.actaneurocomms.org/content/1/1/12phenotype. Neuropathologically, CNS involvement with
LBs was striking and exhibited a unique topography
compared with PD. Thus, further investigations on the
process of LB formation caused by loss of PLA2G6 gene
function may provide new insights into the pathological
mechanism of neuroaxonal dystrophy and LB formation.
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